慢性プラーク性ソーリアシスの現実世界のデータを用いて,リスンキジューマブの薬理 Modeling farmakokinetik-farmakodinamik
Charlotte M Thomas1, Jessica Ruoheng Wei1, David Baudry1
1King's College London, London, UK.
British journal of clinical pharmacology
|February 15, 2026
まとめ
この研究では,リサンキジューマブをソーリアーシスで用いるための薬理動力学/薬理動力学 (PK/PD) モデルが開発されました. このモデルは,慢性性プラーク型牛皮病の治療結果を改善するために,投与量をパーソナライズするのに役立ちます.
科学分野:
- 薬理学 薬理学とは
- 皮膚科 皮膚科について
- 数学的モデリング
背景:
- 慢性性斑塊性牛皮病は,免疫媒介の炎症性疾患である.
- リサンキズマブは,高コストで患者反応が変動する生物学的治療法です.
- パーソナライズされた投与は,牛皮病の治療効果を向上させる可能性があります.
研究 の 目的:
- リサンキズマブのための薬理動力学/薬理動力学 (PK/PD) モデルを開発する.
- リサンキズマブへの曝露と治療への反応との関係を特徴づける.
- パーソナライズされた投薬戦略を psoriasis 患者のために伝えるために.
主な方法:
- 連続的な集団PK/PDモデルは,現実世界のデータを用いて開発されました.
- データには,シリアル製薬動力学 (PK) 測定値とスオリアシス領域および重症度指数 (PASI) 測定値が含まれていました.
- PASIを記述した最大効果ターンオーバーモデルは,病変の発達に対する薬物効果を組み込みました.
主要な成果:
- 固定的吸収率を持つ1つのコンパートメントのPKモデルがデータを記述した.
- 推定クリアランスは0.34L/日,分布量は12.9Lでした.
- 推定された主要パラメータには,ベースラインPASI (23.4),EC50 (0.11 mg/L),およびKaut (0.05日−1) が含まれていました.
結論:
- PKパラメータはrisankizumab.comの臨床試験データと一致しています.
- このモデルは,異なる薬物の間で適用可能な,ソーリアーシス疾患のダイナミクスを捉えています.
- このPK/PDモデルは,パーソナライズされたリサンキジューマブ投与をガイドして,の治療を最適化することができます.
さらに関連する動画
関連する概念動画
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
18
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
18
01:14Pharmacokinetic–Pharmacodynamic Relationship: Model Components
21
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
21
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
17
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
17
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
17
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
17
01:12Analysis of Population Pharmacokinetic Data
822
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
822